Mo1893 Long-Term Outcomes After Primary Infliximab Treatment Failure in Patients With Inflammatory Bowel Disease

Application of the algorithm demonstrated high accuracy by identifying likely VDZ claims only after VDZ's launch, in which a sharp increase in volume at the time of launch was observed, and showing continued growth in the following months.Thus, these results validate that the utilization of the algorithm to assess VDZ claims before assignment of a J-Code is accurate.A total of 2,992 ADA, 2,661 IFX, and 730 VDZ patients met eligibility criteria and are included in this study.IMM combination therapy was observed in 27.0%, 26.4%, and 24.8% of IBD patients on VDZ, IFX, and ADA, respectively.There was no difference in combination therapy rates among UC and Crohn's patients, 28.3% and 26.3% (p=0.566) with VDZ, 25.3% and 24.6% (p=0.642) with ADA and 25.4% and 27.0% (p= 0.336) with IFX, respectively.Of the patients on VDZ IMM combination therapy, 25.1% were treated with methotrexate.Patients taking ADA and IFX were less likely to use combination therapy with methotrexate at 15.9% (p=0.002) and 14.3% (p<0.001),respectively.Conclusions: This is the first study to assess real-world VDZ combination therapy with IMM in the treatment of IBD.We demonstrate that VDZ patients are prescribed IMM combination therapy at similar rates compared to ADA and IFX.